TMO - CareDx: A Robust Transplant Diagnostics Pick For 2020
CareDx (CDNA) is a precision medicine company focused on the ever-growing transplant diagnostics market. The ongoing COVID-19 pandemic has had a significant negative impact on the stock. The stock fell from $21.15 on January 2 all the way down to $13.94 on March 18. The stock has recovered and closed at $23.25 on April 22. Although CareDx is now up 7.79% YTD (year-to-date), there is still much upside left in this relatively COVID-19 resilient stock.
We must understand that almost all of the patients on organ transplant lists are suffering from end-stage diseases.